STAT3 inhibition ameliorates renal interstitial inflammation in MRL/lpr mice with diffuse proliferative lupus nephritis

References

• Morales E, Galindo M, Trujillo H, et al. Update on lupus nephritis: looking for a new vision. Nephron. 2021;145(1):1–13. doi:10.1159/000511268.
   PubMed Web of Science ®Google Scholar
• Parikh SV, Almaani S, Brodsky S, et al. Update on lupus nephritis: core curriculum 2020. Am J Kidney Dis. 2020;76(2):265–281. doi:10.1053/j.ajkd.2019.10.017.
   PubMed Web of Science ®Google Scholar
• Mok CC, Ying KY, Yim CW, et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann Rheum Dis. 2016;75(1):30–36. doi:10.1136/annrheumdis-2014-206456.
   PubMed Web of Science ®Google Scholar
• Mok CC, Ho LY, Ying SKY, et al. Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis. Ann Rheum Dis. 2020;79(8):1070–1076. doi:10.1136/annrheumdis-2020-217178.
   PubMed Web of Science ®Google Scholar
• Prasad N, Kurian J, Agarwal V, et al. Long-term outcomes of lupus nephritis treated with regimens based on cyclophosphamide and mycophenolate mofetil. Lupus. 2020;29(8):845–853. doi:10.1177/0961203320926256.
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721–731. doi:10.1016/S0140-6736(10)61354-2.
   PubMed Web of Science ®Google Scholar
• Cheng H, Zhang X-Y, Yang H-D, et al. Efficacy and safety of belimumab/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus. Front Immunol. 2022;13:911730. doi:10.3389/fimmu.2022.911730.
   PubMed Web of Science ®Google Scholar
• Chen T, Ding X, Chen B. Value of the RIFLE classification for acute kidney injury in diffuse proliferative lupus nephritis. Nephrol Dial Transplant. 2009;24(10):3115–3120. doi:10.1093/ndt/gfp235.
   PubMed Web of Science ®Google Scholar
• Zhu D, Qu Z, Tan Y, et al. Acute kidney injury in chinese patients with lupus nephritis: a large cohort study from a single center. Lupus. 2011;20(14):1557–1565. doi:10.1177/0961203311417035.
   PubMed Web of Science ®Google Scholar
• Chen T, Zhou Y, Zhang J, et al. Long-term predictive value of acute kidney injury classification in diffuse proliferative lupus nephritis with acute kidney injury. BMC Nephrol. 2020;21(1):13. doi:10.1186/s12882-019-1676-4.
   PubMed Web of Science ®Google Scholar
• Chen SY, Liu MF, Kuo PY, et al. Upregulated expression of STAT3/IL-17 in patients with systemic lupus erythematosus. Clin Rheumatol. 2019;38(5):1361–1366. doi:10.1007/s10067-019-04467-8.
   PubMed Web of Science ®Google Scholar
• Wang X, Blanco LP, Carmona-Rivera C, et al. Effects of gasdermin D in modulating murine lupus and its associated organ damage. Arthritis Rheumatol. 2020;72(12):2118–2129.
   PubMed Web of Science ®Google Scholar
• Rasmussen TK, Andersen T, Bak RO, et al. Overexpression of microRNA-155 increases IL-21 mediated STAT3 signaling and IL-21 production in systemic lupus erythematosus. Arthritis Res Ther. 2015;17(1):154. doi:10.1186/s13075-015-0660-z.
   PubMedGoogle Scholar
• Goropevšek A, Holcar M, Avčin T. The role of STAT signaling pathways in the pathogenesis of systemic lupus erythematosus. Clin Rev Allergy Immunol. 2017;52(2):164–181. doi:10.1007/s12016-016-8550-y.
   PubMed Web of Science ®Google Scholar
• Yiu G, Rasmussen TK, Tsai BL, et al. High interferon signature leads to increased STAT1/3/5 phosphorylation in PBMCs from SLE patients by single cell mass cytometry. Front Immunol. 2022;13:833636. doi:10.3389/fimmu.2022.833636.
   PubMed Web of Science ®Google Scholar
• Talaat RM, Mohamed SF, Bassyouni IH, et al. Th1/Th2/Th17/treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: correlation with disease activity. Cytokine. 2015;72(2):146–153. doi:10.1016/j.cyto.2014.12.027.
   PubMed Web of Science ®Google Scholar
• Jeruc J, Vizjak A, Rozman B, et al. Immunohistochemical expression of activated caspase-3 as a marker of apoptosis in glomeruli of human lupus nephritis. Am J Kidney Dis. 2006;48(3):410–418. doi:10.1053/j.ajkd.2006.05.019.
   PubMed Web of Science ®Google Scholar
• Arazi A, Rao DA, Berthier CC, et al. The immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol. 2019;20(7):902–914. doi:10.1038/s41590-019-0398-x.
   PubMed Web of Science ®Google Scholar
• Collison J. Lupus nephritis: targeting bcl-2 prevents nephritis in mice. Nat Rev Rheumatol. 2016;12(7):376–376. doi:10.1038/nrrheum.2016.90.
   PubMedGoogle Scholar
• Yoshida N, He F, Kyttaris VC. T cell-specific STAT3 deficiency abrogates lupus nephritis. Lupus. 2019;28(12):1468–1472. doi:10.1177/0961203319877242.
   PubMed Web of Science ®Google Scholar
• Edwards LJ, Mizui M, Kyttaris V. Signal transducer and activator of transcription (STAT) 3 inhibition delays the onset of lupus nephritis in MRL/lpr mice. Clin Immunol. 2015;158(2):221–230. doi:10.1016/j.clim.2015.04.004.
   PubMed Web of Science ®Google Scholar
• Li Y, Ding T, Chen J, et al. The protective capability of hedyotis diffusa willd on lupus nephritis by attenuating the IL-17 expression in MRL/lpr mice. Front Immunol. 2022;13:943827. doi:10.3389/fimmu.2022.943827.
   PubMed Web of Science ®Google Scholar
• Paquissi FC, Abensur H. The Th17/IL-17 axis and kidney diseases, with focus on lupus nephritis. Front Med (Lausanne). 2021;8:654912. doi:10.3389/fmed.2021.654912.
   PubMed Web of Science ®Google Scholar
• Oliveira CB, Lima CAD, Vajgel G, et al. The role of NLRP3 inflammasome in lupus nephritis. Int J Mol Sci. 2021;22(22):12476. doi:10.3390/ijms222212476.
   PubMed Web of Science ®Google Scholar
• Yung S, Chan TM. Molecular and immunological basis of tubulo-interstitial injury in lupus nephritis: a comprehensive review. Clin Rev Allergy Immunol. 2017;52(2):149–163. doi:10.1007/s12016-016-8533-z.
   PubMed Web of Science ®Google Scholar
• Yung S, Tsang RC, Sun Y, et al. Effect of human anti-DNA antibodies on proximal renal tubular epithelial cell cytokine expression: implications on tubulointerstitial inflammation in lupus nephritis. J Am Soc Nephrol. 2005;16(11):3281–3294. doi:10.1681/ASN.2004110917.
   PubMed Web of Science ®Google Scholar
• Giannakakis K, Faraggiana T. Histopathology of lupus nephritis. Clin Rev Allergy Immunol. 2011;40(3):170–180. doi:10.1007/s12016-010-8207-1.
   PubMed Web of Science ®Google Scholar
• Yung S, Ng CY, Ho SK, et al. Anti-dsDNA antibody induces soluble fibronectin secretion by proximal renal tubular epithelial cells and downstream increase of TGF-beta1 and collagen synthesis. J Autoimmun. 2015;58:111–122.
   PubMed Web of Science ®Google Scholar
• Chen T, Fang Z, Zhu J, et al. ACE2 promoted by STAT3 activation has a protective role in Early-Stage acute kidney injury of murine sepsis. Front Med (Lausanne). 2022;9:890782. doi:10.3389/fmed.2022.890782.
   PubMed Web of Science ®Google Scholar
• Kidney disease: improving global outcomes (KDIGO)acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int. 2012;2(suppl 1):1–138.
   Google Scholar
• Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the international society of nephrology/renal pathology society classification for lupus nephritis: clarification of definitions, and modified national institutes of health activity and chronicity indices. Kidney Int. 2018;93(4):789–796.
   PubMed Web of Science ®Google Scholar
• Park MH, D'Agati V, Appel GB, et al. Tubulointerstitial disease in lupus nephritis: relationship to immune deposits, interstitial inflammation, glomerular changes, renal function, and prognosis. Nephron. 1986;44(4):309–319. doi:10.1159/000184012.
   PubMed Web of Science ®Google Scholar
• Alsuwaida AO. Interstitial inflammation and long-term renal outcomes in lupus nephritis. Lupus. 2013;22(14):1446–1454. doi:10.1177/0961203313507986.
   PubMed Web of Science ®Google Scholar
• Londoño Jimenez A, Mowrey WB, Putterman C, et al. Brief report: tubulointerstitial damage in lupus nephritis: a comparison of the factors associated with tubulointerstitial inflammation and renal scarring. Arthritis Rheumatol. 2018;70(11):1801–1806. doi:10.1002/art.40575.
   PubMed Web of Science ®Google Scholar
• Chang A, Clark MR, Ko K. Cellular aspects of the pathogenesis of lupus nephritis. Curr Opin Rheumatol. 2021;33(2):197–204. doi:10.1097/BOR.0000000000000777.
   PubMed Web of Science ®Google Scholar
• Nakatani K, Fujii H, Hasegawa H, et al. Endothelial adhesion molecules in glomerular lesions: association with their severity and diversity in lupus models. Kidney Int. 2004;65(4):1290–1300. doi:10.1111/j.1523-1755.2004.00537.x.
   PubMed Web of Science ®Google Scholar
• Zhang L, Chen S, Liu Y, et al. P-selectin blockade ameliorates lupus nephritis in MRL/lpr mice through improving renal hypoxia and evaluation using BOLD-MRI. J Transl Med. 2020;18(1):116. doi:10.1186/s12967-020-02284-1.
   PubMed Web of Science ®Google Scholar
• Allam R, Sayyed SG, Kulkarni OP, et al. Mdm2 promotes systemic lupus erythematosus and lupus nephritis. J Am Soc Nephrol. 2011;22(11):2016–2027. doi:10.1681/ASN.2011010045.
   PubMed Web of Science ®Google Scholar
• Harada T, Kyttaris V, Li Y, et al. Increased expression of STAT3 in SLE T cells contributes to enhanced chemokine-mediated cell migration. Autoimmunity. 2007;40(1):1–8. doi:10.1080/08916930601095148.
   PubMed Web of Science ®Google Scholar
• Wu T, Qin X, Kurepa Z, et al. Shared signaling networks active in B cells isolated from genetically distinct mouse models of lupus. J Clin Invest. 2007;117(8):2186–2196. doi:10.1172/JCI30398.
   PubMed Web of Science ®Google Scholar
• Feng Y, Li W, Wang Z, et al. The p-STAT3/ANXA2 axis promotes caspase-1-mediated hepatocyte pyroptosis in non-alcoholic steatohepatitis. J Transl Med. 2022;20(1):497. doi:10.1186/s12967-022-03692-1.
   PubMed Web of Science ®Google Scholar
• Li J, Zhou Y, Liu Y, et al. Sorafenib inhibits caspase-1 expression through suppressing TLR4/stat3/SUMO1 pathway in hepatocellular carcinoma. Cancer Biol Ther. 2018;19(11):1057–1064.
   PubMed Web of Science ®Google Scholar
• Sato S, Zhang XK, Temmoku J, et al. Ets family transcription factor fli-1 promotes leukocyte recruitment and production of IL-17A in the MRL/lpr mouse model of lupus nephritis. Cells. 2020;9(3):714. doi:10.3390/cells9030714.
   PubMed Web of Science ®Google Scholar
• Renner K, Hermann FJ, Schmidbauer K, et al. IL-3 contributes to development of lupus nephritis in MRL/lpr mice. Kidney Int. 2015;88(5):1088–1098.
   PubMed Web of Science ®Google Scholar